Pharma’s Antibiotic Bet Is Still On: Shionogi Drops $600M-Plus to Fuel Swiss Biotech’s Drug Program
Shionogi’s new deal with Swiss biotech BioVersys — a package worth more than $600 million in milestones — is a fresh reminder that serious money is still flowing into the antibiotic space. Even [...]
